ResApp Health Limited (ASX: RAP), the developer of smart phone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received approval to enrol its first patient at the internationally recognised paediatric facility, Princess Margaret Hospital (PMH) in Perth, Western Australia. The study will gather data from patients with a variety of respiratory conditions to further optimise the ResApp algorithms for pneumonia and asthma as well as broadening the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions.
PMH is an additional site to the existing study that is currently underway at Joondalup Health Campus (JHC) that has enrolled in excess of 150 patients. The Company plans to continue enrolment at JHC, in addition to PMH, with a target of approximately 400 patients enrolled at both sites by the end of 2015. These studies are designed to optimise and validate the Company’s machine-learning algorithms. Additional data from increased enrolment has the potential to increase the accuracy of the technology as well as broaden the number of respiratory diseases targeted. The Company is now working with the University of Queensland to analyse the data and expects to receive initial preliminary results in Q3 2015.
Dr Tony Keating, CEO and Managing Director of ResApp Health commented, “We are delighted to be working with PMH to perform this study to further validate and optimise the ResApp algorithms. These studies provide ResApp with the opportunity to bring the power of clinically-proven and regulatory-approved diagnosis of respiratory disease directly to doctors and patients”.
PMH is a 250-bed internationally recognised paediatric facility that treats children and adolescents aged 15 years and under and sees approximately 250,000 patient visits each year.
About ResApp Health Limited
Founded in 2014, ResApp Health Limited, through an exclusive license it has been granted by the University of Queensland (UQ) is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine-learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithms have been successfully tested for pneumonia and asthma diagnosis in clinical proof of concept study by UQ through funding from the Bill and Melinda Gates Foundation. Addressable markets for this technology include licensing to large telehealth service providers for ‘in consultation’ point of care diagnosis, at-home diagnosis and management of respiratory disease through direct sales to consumers and healthcare providers, and working with global aid and humanitarian organisations to deliver tools for low-cost diagnosis in the developing world.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.